Bortezomib (PS-341, Velcade) is a novel, first-in-class proteasomeinhibitor with antitumor activity against a number of hematologic andnonhematologic malignancies.
Terri Davidson, PharmD
Advertisement
Articles by Terri Davidson, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization
2
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
3
Building a Low-Dose Radiation Therapy Program for Benign Disease
4
Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer
5